The Eversense 365 implantable CGM can now integrate with the twiist insulin pump, marking the first time an implantable CGM has been used in an automated insulin delivery system. The sensor sits under the skin of the upper arm, lasts up to one year, and requires only a brief in-office procedure. After a 24-hour initialization and a second calibration, users can connect to the pump and begin automated insulin adjustments.

Unlike traditional CGMs, the year-long sensor reduces the number of startup periods and the variability that comes with frequent replacements. A removable smart transmitter handles communication between the Eversense app and the twiist pump, while weekly fingerstick calibrations keep readings accurate. The transmitter also delivers on-body vibration alerts so users can feel glucose notifications without reaching for their phone.

We dig into all of this in this week’s podcast with Brian Hansen, Chief Commercial Officer at Senseonics, Joanna Mitri, Chief Medical Officer at Sequel Med Tech, and Jill Garner, Associate Director of Clinical Product. During the conversation, we explore how the integration works in real-world use, early feedback from users, access and coverage updates, and what each company is working toward next. Listen above or watch below.

Be sure to follow the podcast on Spotify, Apple Podcasts, or Youtube.

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.